Literature DB >> 25435435

Autophagy and senescence in fibrosing cholangiopathies.

Yasuni Nakanuma1, Motoko Sasaki2, Kenichi Harada2.   

Abstract

Fibrosing cholangiopathy such as primary sclerosing cholangitis (PSC) and biliary atresia (BA) is characterized by biliary epithelial injuries and concentric fibrous obliteration of the biliary tree together with inflammatory cell infiltration. In these diseases, inappropriate innate immunity is reported to contribute more to bile duct pathology as compared with various aspects of "classical" autoimmune diseases. Primary biliary cirrhosis (PBC) is characterized by chronic cholangitis with bile duct loss and classical autoimmune features. Cellular senescence of cholangiocytes and a senescence-associated secretory phenotype lead to the production of proinflammatory cytokines and chemokines that may modify the milieu of the bile duct and then trigger fibroinflammatory responses in PSC and PBC. Furthermore, deregulated autophagy might be involved in cholangiocyte senescence and possibly in the autoimmune process in PBC, and the deregulated innate immunity against enteric microbes or their products that is associated with cholangiocyte senescence might result in the fibrosing cholangitis that develops in PBC and PSC. In BA, innate immunity against double-stranded RNA viruses might be involved in cholangiocyte apoptosis and also in the development of the epithelial-mesenchymal transition of cholangiocytes that results in fibrous obliteration of bile ducts. These recent advances in the understanding of immune-mediated biliary diseases represent a paradigm shift: the cholangiocyte is no longer viewed merely as a passive victim of injury; it is now also considered to function as a potential effector in bile duct pathology.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autophagy; Cellular senescence; Fibrosing cholangiopathy; Innate immunity; Senescence-associated secretory phenotype

Mesh:

Year:  2014        PMID: 25435435     DOI: 10.1016/j.jhep.2014.11.027

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  27 in total

Review 1.  Adult bile duct strictures: differentiating benign biliary stenosis from cholangiocarcinoma.

Authors:  Hiep Nguyen Canh; Kenichi Harada
Journal:  Med Mol Morphol       Date:  2016-06-27       Impact factor: 2.309

Review 2.  Xenobiotics and loss of tolerance in primary biliary cholangitis.

Authors:  Jinjun Wang; Guoxiang Yang; Alana Mari Dubrovsky; Jinjung Choi; Patrick S C Leung
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics.

Authors:  Nina Frey; Sascha Venturelli; Lars Zender; Michael Bitzer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-11-29       Impact factor: 46.802

Review 4.  Liver fibrosis in biliary atresia.

Authors:  Wen-Jun Shen; Gong Chen; Min Wang; Shan Zheng
Journal:  World J Pediatr       Date:  2018-11-21       Impact factor: 2.764

5.  Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells.

Authors:  Ying Wan; Fanyin Meng; Nan Wu; Tianhao Zhou; Julie Venter; Heather Francis; Lindsey Kennedy; Trenton Glaser; Francesca Bernuzzi; Pietro Invernizzi; Shannon Glaser; Qiaobing Huang; Gianfranco Alpini
Journal:  Hepatology       Date:  2017-06-19       Impact factor: 17.425

6.  The Secretin/Secretin Receptor Axis Modulates Ductular Reaction and Liver Fibrosis through Changes in Transforming Growth Factor-β1-Mediated Biliary Senescence.

Authors:  Nan Wu; Fanyin Meng; Tianhao Zhou; Julie Venter; Thao K Giang; Konstantina Kyritsi; Chaodong Wu; Domenico Alvaro; Paolo Onori; Romina Mancinelli; Eugenio Gaudio; Heather Francis; Gianfranco Alpini; Shannon Glaser; Antonio Franchitto
Journal:  Am J Pathol       Date:  2018-07-21       Impact factor: 4.307

7.  Gene-disease associations identify a connectome with shared molecular pathways in human cholangiopathies.

Authors:  Zhenhua Luo; Anil G Jegga; Jorge A Bezerra
Journal:  Hepatology       Date:  2018-01-02       Impact factor: 17.425

8.  Cholestatic liver disease results increased production of reactive aldehydes and an atypical periportal hepatic antioxidant response.

Authors:  Colin T Shearn; Blair Fennimore; David J Orlicky; Yue R Gao; Laura M Saba; Kayla D Battista; Stefanos Aivazidis; Mohammed Assiri; Peter S Harris; Cole Michel; Gary F Merrill; Edward E Schmidt; Sean P Colgan; Dennis R Petersen
Journal:  Free Radic Biol Med       Date:  2019-08-01       Impact factor: 7.376

9.  Downregulation of p16 Decreases Biliary Damage and Liver Fibrosis in the Mdr2/ Mouse Model of Primary Sclerosing Cholangitis.

Authors:  Konstantina Kyritsi; Heather Francis; Tianhao Zhou; Ludovica Ceci; Nan Wu; Zhihong Yang; Fanyin Meng; Lixian Chen; Leonardo Baiocchi; Debjyoti Kundu; Lindsey Kennedy; Suthat Liangpunsakul; Chaodong Wu; Shannon Glaser; Gianfranco Alpini
Journal:  Gene Expr       Date:  2020-05-11

10.  Natural killer cells regulate T cell immune responses in primary biliary cirrhosis.

Authors:  Shinji Shimoda; Satomi Hisamoto; Kenichi Harada; Sho Iwasaka; Yong Chong; Minoru Nakamura; Yuki Bekki; Tomoharu Yoshizumi; Ken Shirabe; Toru Ikegami; Yoshihiko Maehara; Xiao-Song He; M Eric Gershwin; Koichi Akashi
Journal:  Hepatology       Date:  2015-10-16       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.